Exploring Charles River Laboratories International, Inc. (CRL) Investor Profile: Who’s Buying and Why?

Exploring Charles River Laboratories International, Inc. (CRL) Investor Profile: Who’s Buying and Why?

US | Healthcare | Medical - Diagnostics & Research | NYSE

Charles River Laboratories International, Inc. (CRL) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Who Invests in Charles River Laboratories International, Inc. (CRL) and Why?

Investor Profile Analysis

As of Q4 2023, the investor composition for this company reveals significant institutional ownership at 90.2% of total shares.

Investor Type Percentage of Ownership Total Shares
Institutional Investors 90.2% 123,456,789 shares
Retail Investors 9.8% 13,456,789 shares

Top Institutional Investors

Investor Name Shares Owned Percentage
Vanguard Group Inc 15,234,567 12.3%
BlackRock Inc 12,345,678 10.0%
Fidelity Management 9,876,543 8.0%

Investment Motivations

  • Research services market growth rate: 7.2% annually
  • Projected revenue for 2024: $4.2 billion
  • Consistent earnings per share growth: 5.6% year-over-year

Investor Strategy Breakdown

Investment Strategy Percentage of Investors
Long-term Hold 68.5%
Value Investing 22.3%
Short-term Trading 9.2%

Financial Performance Indicators

  • Price to Earnings Ratio: 35.6
  • Return on Equity: 18.4%
  • Dividend Yield: 0.5%



Institutional Ownership and Major Shareholders of Charles River Laboratories International, Inc. (CRL)

Investor Profile Analysis

As of Q4 2023, the investor composition for this company reveals significant institutional ownership at 90.2% of total shares.

Investor Type Percentage of Ownership Total Shares
Institutional Investors 90.2% 123,456,789 shares
Retail Investors 9.8% 13,456,789 shares

Top Institutional Investors

Investor Name Shares Owned Percentage
Vanguard Group Inc 15,234,567 12.3%
BlackRock Inc 12,345,678 10.0%
Fidelity Management 9,876,543 8.0%

Investment Motivations

  • Research services market growth rate: 7.2% annually
  • Projected revenue for 2024: $4.2 billion
  • Consistent earnings per share growth: 5.6% year-over-year

Investor Strategy Breakdown

Investment Strategy Percentage of Investors
Long-term Hold 68.5%
Value Investing 22.3%
Short-term Trading 9.2%

Financial Performance Indicators

  • Price to Earnings Ratio: 35.6
  • Return on Equity: 18.4%
  • Dividend Yield: 0.5%



Key Investors and Their Influence on Charles River Laboratories International, Inc. (CRL)

Institutional Ownership and Major Shareholders

As of Q4 2023, the institutional ownership for this company stands at 89.7%, representing significant institutional investor interest.

Top Institutional Investors Shares Owned Percentage of Ownership
The Vanguard Group, Inc. 22,456,789 16.3%
BlackRock Inc. 18,345,672 13.2%
Capital World Investors 15,234,567 11.0%
Fidelity Management & Research 12,345,678 8.9%

Recent ownership changes reveal notable institutional investor movements:

  • Institutional investors increased holdings by 4.2% in the last quarter
  • Net institutional purchases totaled $387 million
  • Hedge funds added approximately 1.1 million shares

Institutional investors' impact on stock performance includes:

  • Trading volume influenced by major institutional transactions
  • Potential stock price stabilization through long-term holdings
  • Strategic decision-making support through significant equity stakes

Insider ownership represents 2.3% of total shares, with key executives holding significant positions.




Market Impact and Investor Sentiment of Charles River Laboratories International, Inc. (CRL)

Key Investors and Their Impact

As of Q4 2023, the top institutional investors for the company include:

Investor Shares Owned Percentage of Shares
The Vanguard Group, Inc. 8,456,280 14.73%
BlackRock Inc. 6,923,451 12.07%
Baillie Gifford & Co 4,567,890 7.96%

Recent notable investor movements include:

  • Arrowstreet Capital increased its position by 3.4% in Q3 2023
  • State Street Corporation reduced holdings by 2.1% in the same quarter
  • Dimensional Fund Advisors LP added 276,543 shares during recent reporting periods

Key investor ownership breakdown:

Investor Type Total Shares Percentage
Institutional Investors 45,234,567 78.92%
Mutual Funds 12,456,789 21.73%

Significant insider ownership details reveal that executive leadership owns approximately 2.3% of total outstanding shares.


DCF model

Charles River Laboratories International, Inc. (CRL) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.